WO2011056721A3 - Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines - Google Patents

Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines Download PDF

Info

Publication number
WO2011056721A3
WO2011056721A3 PCT/US2010/054668 US2010054668W WO2011056721A3 WO 2011056721 A3 WO2011056721 A3 WO 2011056721A3 US 2010054668 W US2010054668 W US 2010054668W WO 2011056721 A3 WO2011056721 A3 WO 2011056721A3
Authority
WO
WIPO (PCT)
Prior art keywords
poxvirus
subunit
immunoconjugates
antibodies against
presenting cells
Prior art date
Application number
PCT/US2010/054668
Other languages
French (fr)
Other versions
WO2011056721A2 (en
Inventor
Alice P. Taylor
Boby Makabi-Panzu
David M. Goldenberg
Original Assignee
Center For Molecular Medicine And Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/754,140 external-priority patent/US8722047B2/en
Priority claimed from US12/754,740 external-priority patent/US8562988B2/en
Application filed by Center For Molecular Medicine And Immunology filed Critical Center For Molecular Medicine And Immunology
Priority to EP10828938.0A priority Critical patent/EP2496256A4/en
Priority to CN2010800474188A priority patent/CN102573902A/en
Priority to CA2776563A priority patent/CA2776563A1/en
Priority to AU2010315432A priority patent/AU2010315432A1/en
Priority to IN2692DEN2012 priority patent/IN2012DN02692A/en
Publication of WO2011056721A2 publication Critical patent/WO2011056721A2/en
Publication of WO2011056721A3 publication Critical patent/WO2011056721A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention concerns methods and compositions for subunit-based vaccines for inducing immunity against poxvirus infections, such as smallpox. Preferred embodiments concern immunoconjugates comprising one or more subunit antigenic peptides attached to an antibody or fragment thereof that targets antigen-producing cells (APCs). More preferably, the antibody binds to HLA-DR and the antigenic peptide is from an immunomodulating factor, such as the viral IL-18 binding protein (vIL18BP). However, mixtures of antigenic peptides from different viral proteins may also be used. The vaccine is capable of inducing immunity against poxvirus without risk of disseminated infection in immunocompromised hosts or transmission to susceptible contacts.
PCT/US2010/054668 2009-11-05 2010-10-29 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines WO2011056721A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP10828938.0A EP2496256A4 (en) 2009-11-05 2010-10-29 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
CN2010800474188A CN102573902A (en) 2009-11-05 2010-10-29 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
CA2776563A CA2776563A1 (en) 2009-11-05 2010-10-29 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
AU2010315432A AU2010315432A1 (en) 2009-11-05 2010-10-29 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
IN2692DEN2012 IN2012DN02692A (en) 2009-11-05 2010-10-29

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US25836909P 2009-11-05 2009-11-05
US61/258,369 2009-11-05
US25872909P 2009-11-06 2009-11-06
US61/258,729 2009-11-06
US12/754,140 2010-04-05
US12/754,140 US8722047B2 (en) 2005-03-03 2010-04-05 Humanized anti-HLA-DR antibodies
US12/754,740 US8562988B2 (en) 2005-10-19 2010-04-06 Strategies for improved cancer vaccines
US12/754,740 2010-04-06
US37805910P 2010-08-30 2010-08-30
US61/378,059 2010-08-30

Publications (2)

Publication Number Publication Date
WO2011056721A2 WO2011056721A2 (en) 2011-05-12
WO2011056721A3 true WO2011056721A3 (en) 2011-10-13

Family

ID=43970701

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/054668 WO2011056721A2 (en) 2009-11-05 2010-10-29 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines

Country Status (6)

Country Link
EP (1) EP2496256A4 (en)
CN (1) CN102573902A (en)
AU (1) AU2010315432A1 (en)
CA (1) CA2776563A1 (en)
IN (1) IN2012DN02692A (en)
WO (1) WO2011056721A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110038135B (en) 2011-03-17 2021-03-05 伯明翰大学 Redirected immunotherapy
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2014047124A1 (en) * 2012-09-18 2014-03-27 University Of Washington Through Its Center For Commercialization Compositions and methods for delivery of antigens to plasmacytoid dendritic cells
JP2018508481A (en) 2015-02-02 2018-03-29 ザ ユニバーシティ オブ バーミンガム Targeted partial peptide epitope complex having multiple T cell epitopes
CN108289952B (en) 2015-11-19 2021-02-05 雷维托普有限公司 Functional antibody fragment complementation of a two-component system for redirected killing of unwanted cells
CN109187982B (en) * 2018-08-02 2021-06-04 浙江康佰裕生物科技有限公司 Method for screening and identifying TLR vaccine adjuvant
CN109172818B (en) * 2018-08-02 2021-10-22 浙江康佰裕生物科技有限公司 Protein vaccinia vaccine and efficacy detection method thereof
CN113347993A (en) * 2018-10-22 2021-09-03 艾赛澳克莱克斯疗法有限责任公司 Mutant vaccinia virus and uses thereof
CN111474339A (en) * 2020-04-17 2020-07-31 浙江康佰裕生物科技有限公司 Method for labeling poxvirus particles by fluorescence and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291208B1 (en) * 1995-06-07 2001-09-18 Aventis Pasteur Limited Chimeric antibodies for delivery of antigens to selected cells of the immune system
US20090269365A1 (en) * 2005-04-20 2009-10-29 University Of Washington Immunogenic vaccinia peptides and methods of using same
US7612180B2 (en) * 2005-03-03 2009-11-03 Immunomedics, Inc. Humanized L243 antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
WO1994006469A1 (en) * 1992-09-18 1994-03-31 La Jolla Institute For Allergy And Immunology Hiv fusion polypeptide
AU6117896A (en) * 1995-06-07 1996-12-30 Connaught Laboratories Limited Chimeric antibodies for delivery of antigens to selected cel ls of the immune system
US6224870B1 (en) * 1997-01-24 2001-05-01 Genitrix, Ltd. Vaccine compositions and methods of modulating immune responses
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7666400B2 (en) * 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US7527787B2 (en) * 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US6958214B2 (en) * 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
DE60333732D1 (en) * 2002-03-01 2010-09-23 Immunomedics Inc INTERNALIZATION OF ANTI CD74 MONOCLONAL ANTIBODIES AND THEIR USES
AU2003228809A1 (en) * 2002-05-03 2003-11-17 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
US7906118B2 (en) * 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
AU2004232928A1 (en) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
WO2007046893A2 (en) * 2005-10-19 2007-04-26 Ibc Pharmaceuticals, Inc. Methods for generating bioactive assemblies and uses thereof
JP5011277B2 (en) * 2005-04-06 2012-08-29 アイビーシー・ファーマシューティカルズ・インコーポレーテッド Methods and uses for generating stably linked complexes consisting of homodimers, homotetramers or dimeric dimers
AU2006232310B9 (en) * 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
EP1959993B1 (en) * 2005-12-16 2014-11-19 IBC Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
WO2007134037A2 (en) * 2006-05-15 2007-11-22 Immunomedics, Inc. Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
BRPI0911427A2 (en) * 2008-04-10 2015-11-17 Ibc Pharmaceuticals antibody-cytokine dock and lock complex, use of a pharmaceutical composition.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291208B1 (en) * 1995-06-07 2001-09-18 Aventis Pasteur Limited Chimeric antibodies for delivery of antigens to selected cells of the immune system
US7612180B2 (en) * 2005-03-03 2009-11-03 Immunomedics, Inc. Humanized L243 antibodies
US20090269365A1 (en) * 2005-04-20 2009-10-29 University Of Washington Immunogenic vaccinia peptides and methods of using same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 8 December 2008 (2008-12-08), "IL-18 binding protein [Variola virus].", XP008157392, Database accession no. 042049 *
KRUMM ET AL.: "Structural basis for antagonism of human interleukin 18 by poxvirus interleukin 18 -binding protein.", PROC NATL ACAD SCI USA, vol. 105, no. 52, 2008, pages 20711 - 20715, XP008157395 *
MENG ET AL.: "Variola virus IL-18 binding protein interacts with three human IL-18 residues that are part of a binding site for human IL-18 receptor alpha subunit.", VIROLOGY, vol. 358, no. 1, 2007, pages 211 - 220, XP008157403 *
See also references of EP2496256A4 *
VAN VLIET ET AL.: "Poxvirus proteomics and virus-host protein interactions.", MICROBIOL MOL BIOL REV., vol. 73, no. 4, December 2009 (2009-12-01), pages 730 - 749, XP008157390 *

Also Published As

Publication number Publication date
WO2011056721A2 (en) 2011-05-12
EP2496256A4 (en) 2013-07-17
IN2012DN02692A (en) 2015-09-04
CA2776563A1 (en) 2011-05-12
EP2496256A2 (en) 2012-09-12
AU2010315432A1 (en) 2012-04-12
CN102573902A (en) 2012-07-11

Similar Documents

Publication Publication Date Title
WO2011056721A3 (en) Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
MX2021011687A (en) Immunogenic compositions and vaccines comprising african swine fever virus peptides and proteins and uses thereof.
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
WO2012034025A3 (en) Human cytomegalovirus vaccine
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
MX350274B (en) Vaccines for hsv-2.
WO2009128949A3 (en) Compositions of dengue viral proteins and methods of use
WO2009026397A3 (en) Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
WO2016176624A3 (en) Porcine pestvirus, vaccines, and assays
WO2007053188A3 (en) Production of multivalent virus like particles
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
WO2009012487A3 (en) Chimeric varicella zoster virus-virus like particles
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
WO2007052059A3 (en) Changing th1/th2 balance in split influenza vaccines with adjuvants
WO2010149752A3 (en) Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease
MX344103B (en) Newcastle disease virus vectored herpesvirus vaccines.
WO2010079505A3 (en) Combined measles-human papilloma vaccine
WO2008103819A3 (en) Chimeric newcastle disease virus vlps
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
MX2019003682A (en) Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same.
EA201892735A1 (en) COMPOSITION OF VACCINE AGAINST HIV
NZ705526A (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
MX2019003156A (en) Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus.
WO2016116905A9 (en) Cmv antigens and uses thereof
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080047418.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10828938

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010315432

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2692/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2776563

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2010315432

Country of ref document: AU

Date of ref document: 20101029

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010828938

Country of ref document: EP